Acepodia Appoints Jimmy Lai as Chief Financial Officer
March 23, 2021 08:27 ET
|
Acepodia USA
SAN MATEO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced the appointment...
Acepodia to Present at the 6th Annual Innate Killer Summit
March 18, 2021 08:00 ET
|
Acepodia USA
SAN MATEO, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced that Sonny...
Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy Candidates
March 16, 2021 08:00 ET
|
Acepodia USA
SAN MATEO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced the closing of...
Acepodia to Present Late-breaking Poster Presentation Supporting the Potential of its NK Cell Therapy in Solid Tumors at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting
November 09, 2020 08:00 ET
|
Acepodia USA
ACE1702 demonstrates enhanced cytotoxicity against multiple HER2-expressing cell lines and activity under immunosuppressive conditions ACE1702 maintains activity following cryopreservationoNK cell...
Acepodia to Deliver Late-breaking Poster Presentation at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting
November 02, 2020 08:00 ET
|
Acepodia USA
SAN FRANCISCO and TAIPEI, Taiwan, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing novel off-the-shelf cell therapies against solid-tumor and hematologic cancers, today...
Acepodia to Present at the 7th Annual China Healthcare Summit
October 22, 2020 11:02 ET
|
Acepodia USA
SAN FRANCISCO and TAIPEI, Taiwan, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing novel off-the-shelf cell therapies against solid-tumor and hematologic cancers, today...
Acepodia Strengthens Management Team with Appointments of Biotech Industry Veterans
September 01, 2020 08:00 ET
|
Acepodia USA
SAN FRANCISCO and TAIPEI, Taiwan, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing next generation solid tumor and blood-based cancer cell therapies, today announced...
Acepodia Initiates a Phase 1 Clinical Trial Evaluating Allogeneic NK Cell Therapy ACE1702 for Treatment of Solid Tumors
August 18, 2020 07:30 ET
|
Acepodia USA
• ACE1702 is the first antibody-conjugated NK cell therapy in clinical development for the treatment of HER2-expressing solid tumors • Clinical trial expected to enroll up to 24 patients...
Acepodia to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium
July 29, 2020 07:30 ET
|
Acepodia USA
SAN FRANCISCO and TAIPEI, Taiwan, July 29, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing cancer immunotherapies based on its novel Antibody-Cell Conjugation (ACC) and...
Acepodia and JW Therapeutics Enter into Option and License Agreement for Off-the-shelf NK Cell Therapies
July 14, 2020 07:30 ET
|
Acepodia USA
JW therapeutics to receive exclusive licenses to develop and commercialize ACE1702 and ACE1655 in Mainland China, Hong Kong, and Macau Acepodia to receive upfront and milestone payments in addition...